Scholarlink

Background <p>The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are useful prognostic indicators in various cancer types. This study assessed the utility of the mGPS and PNI in predicting survival in men with castration-resistant prostate cancer treated with cabazitaxel.</p> Methods <p>This retrospective cohort study analyzed data on patients who received cabazitaxel for castration-resistant prostate cancer between September 2014 and March 2022. The mGPS was scored on a scale of 0–2 points based on the albumin and C-reactive protein (CRP) levels. PNI was calculated using the albumin level and lymphocyte count. The effect of the mGPS and PNI on survival was assessed using the log-rank test and Cox regression.</p> Results <p>A total of 215 patients were included in the analysis, of whom 103 (47.9%), 64 (29.8%), and 48 (22.3%) had an mGPS of 0, 1, and 2 points, respectively. The median PNI was 42.2 (interquartile range [IQR]: 38.8–45.9). In a risk model using hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and mGPS, the median survival was 19, 13, and 5&#xa0;months in the low-, intermediate-, and high-risk groups, respectively. In a risk model using ALP, LDH, and PNI, the overall survival was 18, 13, and 5&#xa0;months in the low-, intermediate-, and high-risk groups, respectively.</p> Conclusion <p>The mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Takuma Kato,
  • Yoichiro Tohi,
  • Atsushi Takamoto,
  • Ryutaro Shimizu,
  • Kei Daizumoto,
  • Satoshi Katayama,
  • Keita Kobayashi,
  • Hirofumi Morinaka,
  • Kenichi Nishimura,
  • Hideo Fukuhara,
  • Shuichi Morizane,
  • Junya Furukawa,
  • Motoo Araki,
  • Koji Shiraishi,
  • Yoshiyuki Miyaji,
  • Noriyoshi Miura,
  • Keiji Inoue,
  • Mikio Sugimoto

摘要

Background

The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are useful prognostic indicators in various cancer types. This study assessed the utility of the mGPS and PNI in predicting survival in men with castration-resistant prostate cancer treated with cabazitaxel.

Methods

This retrospective cohort study analyzed data on patients who received cabazitaxel for castration-resistant prostate cancer between September 2014 and March 2022. The mGPS was scored on a scale of 0–2 points based on the albumin and C-reactive protein (CRP) levels. PNI was calculated using the albumin level and lymphocyte count. The effect of the mGPS and PNI on survival was assessed using the log-rank test and Cox regression.

Results

A total of 215 patients were included in the analysis, of whom 103 (47.9%), 64 (29.8%), and 48 (22.3%) had an mGPS of 0, 1, and 2 points, respectively. The median PNI was 42.2 (interquartile range [IQR]: 38.8–45.9). In a risk model using hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and mGPS, the median survival was 19, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively. In a risk model using ALP, LDH, and PNI, the overall survival was 18, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively.

Conclusion

The mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel.